This publication has not independently audited current licensing, operations, fulfillment, or dispensing practices
The commentary is not meant to diagnose, treat or replace conventional treatment, and has not been approved or reviewed by the FDA, Health Canada, BMS, European Union Health Commission, South and Central American regulation agencies etc.
Jazmin Aguilera: It sounds like a pretty big downside
Common reasons to switch include a plateau on Wegovy 2.4 mg, tolerability issues, cost considerations as Wegovy gets more expensive at higher doses, or a change in goals or comorbidities
Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells